Ceapro Inc. Reports 2019 Second Quarter and Six-Month Financial Results and Operational Highlights

- Continued execution on transition to a new business model from contract manufacturer to biopharmaceutical company -

- Increased R&D investment focused on the development of delivery systems -

- First six months 2019 sales increased 25% vs first six months 2018 -

EDMONTON, Alberta, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and the first six months ended June 30, 2019.

Corporate and Operational Highlights

Pipeline Development:

  • Announced positive key findings from three oral presentations given at European Meeting on Supercritical Fluids held in Spain from April 12-14, 2019;
  • Started enrollment and randomization of patients for the pilot clinical trial evaluating beta glucan as a potential cholesterol reducer. This is the first clinical trial with a proprietary pharmaceutical grade product in Ceapro’s history;
  • Presented positive results from avenanthramides study at the 2019 American Society of Sports Medicine Meeting on May 31, 2019 in Orlando, FL;
  • Pursued the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks; and
  • Continued the monitoring of stability studies for liquid beta glucan and avenanthramides produced at the new manufacturing site as well as for the pharmaceutical grade dry powder formulation of avenanthramides.


  • Performed technical upgrade of PGX Demo plant;
  • Advanced conversations with interested potential partners to utilize Ceapro’s innovative technology; and
  • Executed on research collaboration projects with the University of Alberta and McMaster University for the impregnation of various bioactives using PGX-processed dry beta glucan and alginate as potential delivery systems for multiple applications in healthcare. 


  • Announced receipt of Site License from Health Canada Natural and Non-Prescription Products Directorate allowing the Company to fabricate, package, label, release and distribute final products; and
  • Signed agreement with OTCQX for listing of Ceapro’s shares in USA and submitted application for due diligence and decision.

Subsequent to Quarter

  • Announced financial contribution agreement with National Research Council of Canada;
  • Announced research funding awarded by Canadian Research for Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) to Ceapro Inc. and McMaster University for development of drug delivery systems using PGX Technology; and
  • Received confirmation of three podium presentations at international scientific conferences to be held in September and October 2019.

“Ceapro remains in a period of exciting ongoing multiple transitions. We have continued to build momentum through establishing our cosmeceuticals base business as a solid foundation to enable the Company to pursue the transition to a new business model from a contract manufacturer to a biopharmaceutical development company,” commented Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro. “While we continue to evaluate various scenarios for large commercial scale up of our disruptive PGX Technology, we are also expanding the focus of our research and development for our two value drivers, beta glucan and avenanthramides. We believe that by leveraging our PGX Technology, we can develop innovative delivery systems composed of new chemical complexes with the opportunity to address areas of significant unmet need in the biopharmaceutical industry.”

Financial Highlights for the Second Quarter and the Six-Month Period Ended June 30, 2019

  • Total sales of $3,054,000 for the second quarter of 2019 and $6,251,000 for the first six-months of 2019 compared to $2,731,000 and $5,001,000 for the comparative periods in 2018. The 25% increase in sales for the first six months is mainly due to a 24% increase in sales of avenanthramides compared to the same period in 2018.
  • Loss before tax of $559,000 for the second quarter of 2019 and $1,195,000 for the first six-months of 2019 compared to a loss before tax of $201,000 and $560,000 for the comparative periods in 2018.
  • Net loss for the first six months of 2019, adjusted for non-cash items, which in 2019 consists primarily of depreciation and amortization, is $25,000, while net loss for the comparative period in 2018, similarly adjusted for non-cash items was $140,000. Similarly, adjusting the gross margin percentage for the increase in depreciation and amortization in the first six months of 2019, would result in a gross margin percentage of 55% as compared to 53% for the same period in 2018.
  • Cash flows generated from operations of $853,000 in 2019 vs cash flows generated from operations of $381,000 in 2018.
  • Positive working capital balance of $4,150,000 as of June 30, 2019.

“We have continued to make progress over the course of the first half of the year in this important transitional period for the Company. The recent announcements on financial contributions from Government entities serve as a testament to the value of Ceapro’s technologies and products and bolster our confidence that Ceapro embodies all the key components to successfully access very large markets and unlock the Company’s full potential,” concluded Mr. Gagnon.

Consolidated Balance Sheets    
  June 30, December 31,
  2019 2018
   $  $
Current Assets    
Cash and cash equivalents   2,248,728   1,844,134
Trade receivables   2,220,208   3,015,344
Other receivables   22,651   46,899
Inventories (note 4)   903,261   710,708
Prepaid expenses and deposits   351,518   518,219
    5,746,366   6,135,304
Non-Current Assets    
Investment tax credits receivable   607,700   607,700
Deposits   88,340   88,340
Licences (note 5)   22,958   24,440
Property and equipment (note 6)   20,371,052   17,947,967
Deferred tax assets   520,872   520,872
    21,610,922   19,189,319
TOTAL ASSETS   27,357,288   25,324,623
Current Liabilities    
Accounts payable and accrued liabilities   1,067,470   949,878
Current portion of long-term debt (note 7)   193,061   336,956
Current portion of lease liabilities (note 8)   258,281   - 
Current portion of CAAP loan (note 10)   77,858   72,942
    1,596,670   1,359,776
Non-Current Liabilities    
Long-term debt (note 7)   15,974   110,350
Long-term lease liabilities (note 8)   2,909,921   - 
CAAP loan (note 10)   124,861   115,216
Deferred tax liabilities   524,280   524,280
    3,575,036   749,846
TOTAL LIABILITIES   5,171,706   2,109,622
Share capital (note 9 (b))   16,341,924   16,320,522
Contributed surplus (note 9 (e))   4,645,842   4,501,444
Retained earnings   1,197,816   2,393,035
    22,185,582   23,215,001
TOTAL LIABILITIES AND EQUITY   27,357,288   25,324,623

Consolidated Statements of Net Loss and Comprehensive Loss

  Quarters Ended June 30,   Six Months Ended June 30,  
  2019   2018   2019   2018  
  $   $   $   $  
Revenue (note 16) 3,053,727   2,731,375   6,250,657   5,000,955  
Cost of goods sold 1,592,293   1,177,636   3,432,591   2,345,930  
Gross margin 1,461,434   1,553,739   2,818,066   2,655,025  
Research and product development 811,894   659,226   1,612,398   998,039  
General and administration 878,620   765,984   1,611,639   1,513,720  
Sales and marketing 95,102   31,598   202,780   47,621  
Finance costs (note 13) 52,813   15,481   161,187   86,384  
Income (loss) from operations (376,995 ) 81,450   (769,938 ) 9,261  
Other expenses (note 12) (181,596 ) (282,743 ) (425,281 ) (569,161 )
Loss before tax (558,591 ) (201,293 ) (1,195,219 ) (559,900 )
Income taxes        
Current tax recovery -   -   -   -  
Deferred tax benefit -   35,600   -   99,000  
Income tax benefit -   35,600   -   99,000  
Total comprehensive loss for the period (558,591 ) (165,693 ) (1,195,219 ) (460,900 )
Net loss per common share (note 19):        
Basic (0.01 ) (0.00 ) (0.02 ) (0.01 )
Diluted (0.01 ) (0.00 ) (0.02 ) (0.01 )
Weighted average number of common shares outstanding (note 19):        
Basic 77,053,836   75,756,859   77,050,330   75,734,815  
Diluted 77,053,836   75,756,859   77,050,330   75,734,815  

The complete financial statements are available for review on SEDAR at  https://sedar.com/ and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Ceapro Logo.jpg

Source: Ceapro Inc.